Bruno Sarmento graduated in Pharmaceutical Sciences and is PhD in Pharmaceutical Nanotechnology at Univ Porto, in collaboration with Queen’s Univ, Univ Copenhagen and Univ Santiago de Compostela. He was post-doc fellow at Univ Porto in collaboration with Univ Copenhagen. In 2012 he became Associated Researcher at INEB, now part of i3S, Assistant Researched in 2016 and Principal Investigator in 2019, where he leads the Nanomedicines & Translational Drug Delivery group. He is currently invited Associate Professor at IUCS. He was Visiting Professor at UniOeste (BR) between 2015-2017 and at Shanghai Jiao Tong University (CH) between 2022-2024.
His research interests cover cutting-edge drug delivery systems, with a keen focus on nanomedicine. He has made significant and multidisciplinary contributions on engineering nanomedicines, multistage macroplatforms and 3D multicompartmental cell-based models, closely resembling the basic characteristics of healthy and injured tissues, as reliable pre-clinical platforms for drug and nanomedicines efficacy screening.
He has nurtured scientists and innovators by education and training, supervising 18 Post-Docs, 55 PhD and 40 MSc students and 20 researcher assistants. His group holds vary scientific backgrounds, diversity by gender (20% male/80% female), including researchers from more than 15 countries.
He hosted more than 25 mobility/foreigner PhD students, fostering a vibrant exchange of ideas and expertise and resulting in multiple publications in collaboration with international co-authors.
His research garnered international recognition, evident in his publication record of over 500 papers (>23000 citations, H-index 76), and more than 60 invited talks in international meetings in 20 countries. He attracted competitive funding from national (FCT, CCDR-N, CESPU) and international (EC, NIH, CAPES, FAPESP, Crohn’s & Colitis Foundation) grants, and partnership with pharmaceutical industries.
He serves the i3S Board of Directors since 2020, Director-at-Large and Secretary of the Controlled Release Society (CRS) and member of CRS College of Fellows. He is editor of Eur J Pharm Sci and Drug Deliv Transl Res, and Advisory Board of others as J Control Rel and Exp Opin Drug Deliv. He is a regular reviewer for high rank journals (Nat Nanotechnol, Sci Adv, Nat Com, Adv Mat, J Control Rel) and funding agencies (FNRS (BE), FWO(BE), CNCS (RO), FCT (PT), NSC (PL), ANR (FR), CNPq (BR), ERC, MC Actions, PathFinder, FetOpen (EC)).
Selected Publications
Establishment of a 3D multi-layered in vitro model of inflammatory bowel disease. Journal of Controlled Release377:675-688, 2025. [Journal: Article] [IF: 10.5 (*)]
DOI: 10.1016/j.jconrel.2024.11.070 SCOPUS: 85210380595
Barros A.S., Pinto S., Viegas J., Martins C., Almeida H., Alves I., Pinho S., Nunes R., Harris A., Sarmento B.
Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. Small20(45):, 2024. [Journal: Article] [IF: 13 (*)]
DOI: 10.1002/smll.202402502 SCOPUS: 85198399661
Viegas J., Costa S., Dias S., Pereira C.L., Sarmento B.
Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening. Advanced Science:, 2024. [Journal: Article] [IF: 14.3 (*)]
DOI: 10.1002/advs.202408707 SCOPUS: 85207629059
Carvalho A.M., Bansal R., Barrias C.C., Sarmento B.
The Material World of 3D-Bioprinted and Microfluidic-Chip Models of Human Liver Fibrosis. Advanced Materials36(2):, 2024. [Journal: Review] [CI: 8] [IF: 27.4 (*)]
DOI: 10.1002/adma.202307673 SCOPUS: 85177197944
Pinto S., Hosseini M., Buckley S.T., Yin W., Garousi J., Gräslund T., van Ijzendoorn S., Santos H.A., Sarmento B.
Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide. Journal of Controlled Release366:621-636, 2024. [Journal: Article] [CI: 8] [IF: 10.5 (*)]
DOI: 10.1016/j.jconrel.2024.01.015 SCOPUS: 85182731048
Joyce P., Allen C.J., Alonso M.J., Ashford M., Bradbury M.S., Germain M., Kavallaris M., Langer R., Lammers T., Peracchia M.T., Popat A., Prestidge C.A., Rijcken C.J.F., Sarmento B., Schmid R.B., Schroeder A., Subramaniam S., Thorn C.R., Whitehead K.A., Zhao C.X., Santos H.A.
A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology19(11):1597-1611, 2024. [Journal: Review] [CI: 4] [IF: 38.1 (*)]
DOI: 10.1038/s41565-024-01754-7 SCOPUS: 85203266366
Martins C., Araújo M., Malfanti A., Pacheco C., Smith S.J., Ucakar B., Rahman R., Aylott J.W., Préat V., Sarmento B.
Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting. Small19(22):, 2023. [Journal: Article] [CI: 17] [IF: 13]
DOI: 10.1002/smll.202300029 SCOPUS: 85149319530
Moura R.P., Carvalho E.D., Martins C., des Rieux A., Pêgo A.P., Sarmento B.
Functionalized retinoic acid lipid nanocapsules promotes a two-front attack on inflammation and lack of demyelination on neurodegenerative disorders. Journal of Controlled Release358:43-58, 2023. [Journal: Article] [CI: 7] [IF: 10.5]
DOI: 10.1016/j.jconrel.2023.04.034 SCOPUS: 85153574869
Martins C., Pacheco C., Moreira-Barbosa C., Marques-Magalhães Â., Dias S., Araújo M., Oliveira M.J., Sarmento B.
Glioblastoma immuno-endothelial multicellular microtissue as a 3D in vitro evaluation tool of anti-cancer nano-therapeutics. Journal of Controlled Release353:77-95, 2023. [Journal: Article] [CI: 8] [IF: 10.5]
DOI: 10.1016/j.jconrel.2022.11.024 SCOPUS: 85143777496
Almeida A., Castro F., Resende C., Lúcio M., Schwartz S., Sarmento B.
Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer. Journal of Controlled Release349:731-743, 2022. [Journal: Article] [CI: 26] [IF: 10,8]
DOI: 10.1016/j.jconrel.2022.07.029 SCOPUS: 85135197951